CA2929199C - Crystalline beta-lactamase inhibitor - Google Patents

Crystalline beta-lactamase inhibitor Download PDF

Info

Publication number
CA2929199C
CA2929199C CA2929199A CA2929199A CA2929199C CA 2929199 C CA2929199 C CA 2929199C CA 2929199 A CA2929199 A CA 2929199A CA 2929199 A CA2929199 A CA 2929199A CA 2929199 C CA2929199 C CA 2929199C
Authority
CA
Canada
Prior art keywords
methyl
methy1
compound
formula
dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929199A
Other languages
English (en)
French (fr)
Other versions
CA2929199A1 (en
Inventor
Alessandro LAMONICA
Marco Forzatti
Stefano Biondi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allecra Therapeutics SAS
Original Assignee
Allecra Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2929199(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics SAS filed Critical Allecra Therapeutics SAS
Publication of CA2929199A1 publication Critical patent/CA2929199A1/en
Application granted granted Critical
Publication of CA2929199C publication Critical patent/CA2929199C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2929199A 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor Active CA2929199C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1319776.9 2013-11-08
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
GB1408643.3 2014-05-15
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Publications (2)

Publication Number Publication Date
CA2929199A1 CA2929199A1 (en) 2015-05-14
CA2929199C true CA2929199C (en) 2023-01-03

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929199A Active CA2929199C (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Country Status (14)

Country Link
US (2) US20160289245A1 (cg-RX-API-DMAC7.html)
EP (1) EP3066103A1 (cg-RX-API-DMAC7.html)
JP (2) JP7045795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160081964A (cg-RX-API-DMAC7.html)
CN (1) CN105873935B (cg-RX-API-DMAC7.html)
AU (1) AU2014345507B2 (cg-RX-API-DMAC7.html)
CA (1) CA2929199C (cg-RX-API-DMAC7.html)
CL (1) CL2016001097A1 (cg-RX-API-DMAC7.html)
EA (1) EA031348B1 (cg-RX-API-DMAC7.html)
GB (2) GB201319776D0 (cg-RX-API-DMAC7.html)
IL (1) IL245386A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016005869A (cg-RX-API-DMAC7.html)
PE (1) PE20160890A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015067787A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
ATE219085T1 (de) * 1997-12-29 2002-06-15 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
EA030662B1 (ru) * 2010-11-25 2018-09-28 Аллекра Терапойтикс Гмбх β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
US20150140059A1 (en) * 2012-05-07 2015-05-21 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
JP2016517888A (ja) * 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
US9657052B2 (en) * 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols

Also Published As

Publication number Publication date
CA2929199A1 (en) 2015-05-14
AU2014345507A1 (en) 2016-05-19
MX2016005869A (es) 2017-01-05
CL2016001097A1 (es) 2016-12-02
AU2014345507B2 (en) 2018-11-22
JP2016535054A (ja) 2016-11-10
CN105873935B (zh) 2019-03-19
US20190071456A1 (en) 2019-03-07
PE20160890A1 (es) 2016-08-25
JP7346485B2 (ja) 2023-09-19
EP3066103A1 (en) 2016-09-14
JP7045795B2 (ja) 2022-04-01
EA201690963A1 (ru) 2016-10-31
CN105873935A (zh) 2016-08-17
EA031348B1 (ru) 2018-12-28
GB201408643D0 (en) 2014-07-02
WO2015067787A1 (en) 2015-05-14
JP2021102642A (ja) 2021-07-15
US11124526B2 (en) 2021-09-21
GB201319776D0 (en) 2013-12-25
US20160289245A1 (en) 2016-10-06
KR20160081964A (ko) 2016-07-08
IL245386A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
EP3299370B1 (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
JP2014530805A (ja) アジルサルタンの結晶形並びにその製造及び使用
EP4327828A2 (en) Solid forms of ceftolozane
EP2468762A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
JP7346485B2 (ja) 結晶性β－ラクタマーゼ阻害剤
EP1749013A2 (en) Stable amorphous cefdinir
WO2017042683A1 (en) Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin
JPH04500819A (ja) 有機化合物の、または関連する改善
US8871927B2 (en) Method for purifying Ceftizoxime sodium
WO2016108204A1 (en) Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
RU2074858C1 (ru) Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция
BR112016010282B1 (pt) Composição farmacêutica compreendendo um inibidor de betalactamase cristalino
CA2945900C (en) Method of forming methyl penam derivatives
HK40106682A (en) Solid forms of ceftolozane
CN105461739A (zh) 结晶头孢嗪脒钠及其制备方法和用途
JPH0314586A (ja) セフェム化合物及びその製造法
HK1250030B (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ725121B2 (en) Methods for Preparing Penams
MX2008014836A (es) Sales y modificaciones del cristal de las mismas.
HK1234738B (en) Methods for preparing penams

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191031

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251027

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251027

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260313

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260313

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729